carvykti’s strong sales fuel stock’s potential By Investing.com
Legend Biotech Corporation (NASDAQ:LEGN) has been making waves in the biotechnology sector with its flagship product, Carvykti, a CAR-T therapy for multiple myeloma. As the company continues to expand its market presence and manufacturing capabilities, investors and analysts are closely watching its performance and future prospects. According to InvestingPro data, Legend Biotech’s market capitalization stands at $5.78 billion, with the stock currently trading near its 52-week low, suggesting potential value opportunity for investors.
Want deeper insights? InvestingPro subscribers get access to over 10 additional exclusive tips and comprehensive financial metrics for LEGN. This comprehensive analysis delves into Legend Biotech’s…
